To the Editor Recently, anti–programmed cell death protein 1 drugs have shown durable response in melanoma, non–small-cell lung cancers, and renal cell cancers.1,2 The article “Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression” by Sanlorenzo et al3 describes interesting clinical findings, yet we have the following comments regarding the statistical analyses.
Shelley Ji Eun Hwang, Karen Byth, Pablo Fernandez-Penas. Time-Dependent Measurement of Adverse Events. JAMA Dermatol. 2015;151(12):1392. doi:10.1001/jamadermatol.2015.3579